Viewing StudyNCT03164616



Ignite Creation Date: 2024-05-06 @ 10:06 AM
Last Modification Date: 2024-10-26 @ 12:24 PM
Study NCT ID: NCT03164616
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-06-12
First Post: 2017-05-22

Brief Title: Study of Durvalumab Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer POSEIDON
Sponsor: AstraZeneca
Organization: AstraZeneca

Conditions & Keywords Data

Conditions:
Name
Non Small Cell Lung Cancer NSCLC
Keywords:
Name View
Overall survival OS View
NSCLC View
Programmed cell death ligand 1 PD-L1 View
Durvalumab View
Tremelimumab View
Progression-free survival PFS View